Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics

• Published in: Journal of psychopharmacology (Oxford) Vol. 33; no. 4; p. 522
• Main Authors: Saiz-Rodríguez, Miriam, Ochoa, Dolores, Belmonte, Carmen, Román, Manuel, Vieira de Lara, Danilo, Zubiaur, Pablo, Koller, Dora, Mejía, Gina, Abad-Santos, Francisco
• Format: Journal Article
• Language: English
• Published: United States 01.04.2019
• Subjects: Acetamides - blood; Acetamides - pharmacokinetics; Acetamides - pharmacology; Adolescent; Adult; Alleles; Antidepressive Agents - blood; Antidepressive Agents - pharmacokinetics; Antidepressive Agents - pharmacology; ATP Binding Cassette Transporter, Subfamily B - genetics; Blood Pressure - drug effects; Cytochrome P-450 CYP1A2 - genetics; Cytochrome P-450 CYP2C9 - genetics; Electrocardiography - drug effects; Female; Genotype; Healthy Volunteers; Heart Rate - drug effects; Humans; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide - genetics; Young Adult; pharmacokinetics; Pharmacogenetics; cytochrome P450; agomelatine; antidepressant

Agomelatine is an agonist of the melatoninergic receptors used for the treatment of depression. Our aim was to evaluate the effect of genetic polymorphisms in metabolising enzymes and the P-glycoprotein transporter on agomelatine pharmacokinetics and pharmacodynamics. Twenty-eight healthy volunteers...